BMS-955176 + atazanavir

BMS-955176 + atazanavir is an **investigational combination therapy for HIV-1 infection**. BMS-955176 is a second-generation small molecule maturation inhibitor developed to block one of the final cleavage steps in the HIV-1 Gag polyprotein, leading to the production of immature, non-infectious HIV-1 particles. Atazanavir is an HIV-1 protease inhibitor that prevents viral polyprotein cleavage, thereby inhibiting viral replication. Used together, these drugs target distinct late stages in the virus lifecycle, potentially offering a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for patients with resistance or intolerance to standard treatments. The combination has shown **antiviral activity comparable to standard regimens** and a favorable short-term safety profile in phase 2 studies[1][2][4].